Quick overview: Saxenda at a glance
- What it is: Saxenda is liraglutide 3 mg, a daily GLP-1 injection approved for chronic weight management.
- Who it’s for: Adults with BMI ≥30, or ≥27 with weight‑related conditions, alongside diet and activity changes.
- How it compares: Older GLP‑1 taken daily; newer weekly options (e.g., Wegovy) may offer greater average weight loss for many users.
- Access: Prescription only via GP, specialist or telehealth; stock levels can vary by pharmacy and city.
- Costs: Usually private (non‑PBS) for weight loss; many report $350–$600+ per month depending on dose and pharmacy.
What is Saxenda and how it works
Saxenda is the brand name for liraglutide 3 mg, a GLP‑1 receptor agonist that helps regulate appetite and satiety. It slows gastric emptying and enhances fullness signals, which can support lower calorie intake when combined with a reduced‑energy diet and increased physical activity.
Differences vs other GLP‑1 and related options in Australia:
- Wegovy (semaglutide): Weekly injection; many trials show higher average weight loss vs daily liraglutide.
- Ozempic (semaglutide): Weekly; TGA‑approved for type 2 diabetes (weight loss use is off‑label).
- Mounjaro (tirzepatide): Weekly dual‑agonist for diabetes; weight management indications evolving.
- Rybelsus (oral semaglutide): Tablet for diabetes; different absorption and dosing considerations.
- Trulicity (dulaglutide): Weekly GLP‑1 for diabetes; sometimes compared for convenience and access.
Who may be eligible in Australia
Prescribers typically consider Saxenda for adults who:
- Have a BMI ≥30; or BMI ≥27 with a weight‑related comorbidity (e.g., hypertension, dyslipidaemia, obstructive sleep apnoea, insulin resistance or type 2 diabetes).
- Are prepared to combine medication with nutritionally appropriate dietary change and increased activity.
- Don’t have contraindications (see key warnings below) and can attend appropriate follow‑up.
Children and adolescents may be handled under specialist care with different criteria. Final suitability is determined by your clinician after reviewing your medical history, medications and goals.
How to access Saxenda in Australia
- Book a consult with a GP, obesity specialist or a reputable telehealth clinic.
- Assessment: Discuss weight history, comorbidities, medications, prior GLP‑1 experience and lifestyle plans.
- Script & supply: If suitable, your prescriber issues a prescription. Your pharmacy confirms stock or places an order.
- Follow‑up: Dose titration, side-effect review and progress checks are essential for safety and results.
Supply can fluctuate. If a local pharmacy is out of stock, ask your prescriber or clinic to help source alternatives or temporary substitutes.
Saxenda cost in Australia
For weight management, Saxenda is generally not PBS‑listed, so most people pay private prices. Reported monthly costs often fall around AUD $350–$600+ depending on dose used, pharmacy and city. Needles and sharps disposal are additional considerations.
- Costs vary by pharmacy and may change with supply conditions.
- Your actual monthly cost depends on your maintenance dose and how many pens you need.
Dosing, titration and use
Saxenda is a once‑daily subcutaneous injection (abdomen, thigh or upper arm). A common titration is:
- Week 1: 0.6 mg daily
- Week 2: 1.2 mg daily
- Week 3: 1.8 mg daily
- Week 4: 2.4 mg daily
- Week 5 onward: 3.0 mg daily (maintenance if tolerated)
Your clinician may slow the titration if side effects occur. If you miss a dose, follow the product directions or your prescriber’s advice. Store unused pens in the refrigerator and keep in‑use pens as directed in the product information (observe expiry timelines and temperature limits).
Side effects and key warnings
Common: Nausea, vomiting, diarrhoea or constipation, reduced appetite, reflux/indigestion, headache, injection‑site reactions, fatigue. GI effects are usually dose‑related and often improve after the titration phase.
Serious or important warnings (seek medical advice promptly if suspected):
- Pancreatitis: Severe abdominal pain that may radiate to the back, with or without vomiting.
- Gallbladder disease: Upper right abdominal pain, fever, jaundice.
- Thyroid C‑cell tumours: Contraindicated if you or a family member has had medullary thyroid carcinoma or MEN2.
- Kidney injury/dehydration: From prolonged vomiting/diarrhoea—maintain hydration and seek care if unwell.
- Hypoglycaemia: Risk increases if used with insulin or sulfonylureas—discuss dose adjustments with your prescriber.
- Pregnancy and breastfeeding: Not recommended; discuss contraception and planning with your clinician.
- Severe GI disease (e.g., gastroparesis): Use may be inappropriate—confirm with your doctor.
Saxenda vs alternatives: how to evaluate your options
If convenience or expected weight loss are priorities, compare Saxenda with weekly GLP‑1 options and newer agents:
- Wegovy vs Saxenda: Weekly semaglutide vs daily liraglutide—average results and dosing convenience.
- Saxenda vs Ozempic: Weight loss suitability, indications and availability differences.
- Mounjaro (tirzepatide): Dual‑agonist; check current Australian indication and supply status.
Also see the broader comparisons and brand guides:
PBS status and supply considerations
- PBS: Saxenda is generally not subsidised on the PBS for weight management. Expect private pricing unless your use falls under a different, specific indication arranged by your prescriber.
- Supply: GLP‑1 demand continues to influence availability. Pharmacies may have back‑orders or limited stock. Your clinic can help coordinate alternatives if required.
- Importing: Personal importation of prescription medicines is regulated and carries risks (cold‑chain, counterfeit, seizure). Most people use local prescriptions and pharmacies for safety and product integrity.
Prescription, monitoring and when to review
Your prescriber will usually set review points to assess tolerability, dose progression and weight‑loss response. If minimal benefit is seen after a set period at maintenance dose, guidelines often suggest reconsidering therapy or switching to another option.
Frequently asked questions
Is Saxenda the same as Victoza?
Both contain liraglutide, but Victoza is approved for diabetes at lower doses, while Saxenda is the 3 mg dose specifically indicated for weight management. Indications and PBS status differ.
How quickly might I notice changes?
Some people notice appetite changes during titration. Meaningful weight change is typically assessed over 12–16 weeks once you reach and tolerate a maintenance dose, alongside diet and activity adjustments.
Can I drink alcohol while on Saxenda?
Alcohol can worsen GI side effects and impact calorie goals. Discuss safe use and limits with your clinician, especially if you have pancreatitis risk factors.
What if I can’t tolerate the 3.0 mg dose?
Your prescriber may slow titration or hold at a lower dose. If side effects persist or benefits are limited, they may recommend switching to another therapy.
Do I need to keep Saxenda in the fridge?
Unopened pens should be refrigerated. After first use, follow the product information for in‑use storage limits and time‑to‑discard. Keep within the recommended temperature range.
Do I have to stay on Saxenda long‑term?
Weight management is chronic; stopping medication often reduces its appetite effects. Many patients and prescribers plan medium‑ to longer‑term strategies and revisit the plan based on goals, side effects and costs.
Get personalised help with Saxenda, access and alternatives
Send us a few details and we’ll point you to reputable prescribers, current pricing ranges and brand alternatives in Australia.
Information on this site is general and not a substitute for medical advice. Your prescriber will confirm suitability, dosing and monitoring.
Final takeaway
Saxenda is a well‑known daily GLP‑1 option for weight management in Australia. While many people prefer newer weekly injections, Saxenda remains a viable choice for those who tolerate and respond to liraglutide. Access, cost and supply vary—compare options before you decide.